Lithium

Lithium

SCHEMBL7182340

CC(C)COc1ccc(PC(=O)c2c(Cl)cccc2Cl)c(OCC(C)C)c1.[Li]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FOS P01100 2/20 0.39
JUN P05412 2/20 0.39
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
NR1H4 Q96RI1 2/20 0.37
PTGER1 P34995 4/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
PDK2 Q15119 1/20 0.36
XDH P47989 1/20 0.36
TRIM24 O15164 1/20 0.36
ABL1 P00519 1/20 0.35
SLC16A3 O15427 1/20 0.35
SLC16A1 P53985 1/20 0.35
KAT6A Q92794 1/20 0.35
MEN1 O00255 1/20 0.35
ACACB O00763 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182327 0.98 FOS (0.41) FOSJUNKMT2AALDH1A1MAPT
Lithium SCHEMBL7181512 0.94 FOS (0.36) FOSJUNKMT2AALDH1A1MAPT
Lithium SCHEMBL7188985 0.94 SLC16A3 (0.36) FOSJUNKMT2AALDH1A1MAPT
SCHEMBL7188974 0.92 FOS (0.38) FOSJUNKMT2AALDH1A1MAPT
SCHEMBL7181505 0.92 FOS (0.38) FOSJUNKMT2AALDH1A1MAPT
Lithium SCHEMBL7188514 0.88 FFAR1 (0.39) FOSJUNALDH1A1NR1H4SIRT2
Lithium SCHEMBL7187564 0.87 MAPT (0.38) FOSJUNMAPTNR1H4SIRT2
SCHEMBL7188508 0.86 FOS (0.41) FOSJUNALDH1A1NR1H4SIRT2
SCHEMBL7176019 0.86 KMT2A (0.41) FOSJUNKMT2AALDH1A1MAPT
SCHEMBL7187557 0.85 FOS (0.40) FOSJUNMAPTNR1H4SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FOS 2702/4885JUN 4136/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FOS 2549/4885JUN 3781/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.